Trial Profile
A Retrospective study to evaluate the impact of co-morbidities and BMI on Ruxolitinib treatment responses in patients with Myelofibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2019 Results assessing assessed the impact of comorbidities and BMI on clinical responses, overall survival and maintenance of ruxolitinib dose in a large cohort of MF patients published in the Annals of Hematology
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 20 Jan 2017 New trial record